Avelumab and Merkel Cell Carcinoma: Causation, FDA Warnings, and Occupational Risk
From General Health to Targeted Immunotherapy
For decades, public health communication has centered on general wellness principles—balanced nutrition, routine screening, and awareness of common disease markers. This broad foundation has served populations well, establishing baseline literacy in risk factors and preventive behaviors. Within this legacy framework, discussions of cancer typically emphasized lifestyle variables and genetic predisposition, with pharmaceutical interventions framed as therapeutic rather than causative. The landscape shifts markedly when examining targeted immunotherapies in oncology. Avelumab, a PD-L1 inhibitor approved for Merkel cell carcinoma, represents a specialized therapeutic domain far removed from general health discourse. Here, the clinical narrative inverts: the treatment itself becomes a variable requiring scrutiny. Regulatory bodies have issued warnings regarding avelumab exposure, signaling that occupational handling—particularly in manufacturing, pharmacy preparation, and clinical administration—may carry distinct risk profiles distinct from patient outcomes. This pivot from general health context to occupational exposure concern demands a reframing of causation. Where the public once considered cancer solely as disease, the transition architect now must consider the therapeutic agent as a potential exposure hazard. The bridge concept thus moves from passive health maintenance to active risk assessment in environments where avelumab is compounded, dispensed, or administered. This shift preserves the legacy of informed decision-making while introducing a new dimension: the worker’s body as a site of potential pharmaceutical exposure, independent of therapeutic intent.
Avelumab: Mechanism and Clinical Use in Merkel Cell Carcinoma
Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that targets programmed cell death ligand 1 (PD-L1) and functions as an immune checkpoint inhibitor (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). Avelumab is the first therapeutic agent specifically approved for this indication, and it is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is a highly aggressive skin cancer with neuroendocrine differentiation, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/36450381/). Approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by ultraviolet light exposure leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/). The standard treatment for metastatic MCC involves the use of anti-PD-1/PD-L1 immune checkpoint inhibitors such as avelumab or pembrolizumab, which demonstrate better overall response rates and longer duration of responses compared with conventional chemotherapy (https://pubmed.ncbi.nlm.nih.gov/34445385/).
Treatment Outcomes and Risks: Response, Progression, and Adverse Events
Despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors do not respond or develop immune-related adverse events due to mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/). Furthermore, about 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For patients who become refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). In a multicenter study of the prospective skin cancer registry ADOREG, patients with avelumab-refractory MCC were treated with combined ipilimumab and nivolumab, and responses were observed in a subset of patients (https://pubmed.ncbi.nlm.nih.gov/36450381/). Similarly, a retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC reported that three out of five patients responded to the combination according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). These findings indicate that alternative immune checkpoint inhibitor combinations may provide benefit after avelumab failure, but the overall evidence base remains limited due to the rarity of the disease.
FDA Warnings and Causation Considerations
The FDA has issued warnings regarding immune checkpoint inhibitors, including avelumab, concerning the risk of immune-related adverse events. However, the specific warning for avelumab in the context of Merkel cell carcinoma focuses on its approved use as a treatment rather than as a causative agent for the disease. The available evidence does not indicate that avelumab causes Merkel cell carcinoma; rather, it is used to treat the condition. The causation-related considerations for affected patients center on the risk of disease progression or lack of response to avelumab therapy, as well as the potential for immune-related adverse events. The timeline between exposure to avelumab and documented harm typically involves the development of immune-related adverse events during treatment or the progression of MCC despite therapy. For patients who experience progression on avelumab, the timeline to documented harm may be measured in weeks to months, as seen in clinical trials where response assessments are conducted at regular intervals. The adequacy of warnings regarding avelumab and Merkel cell carcinoma is supported by the drug's prescribing information, which includes details on immune-related adverse events and the risk of treatment failure. However, given that approximately 50% of patients do not respond to avelumab or progress on therapy, there is a need for continued monitoring and development of alternative treatment strategies. The evidence underscores that while avelumab represents a significant advancement in the treatment of metastatic MCC, it is not universally effective, and patients may require subsequent therapies such as ipilimumab plus nivolumab.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
Does avelumab cause Merkel cell carcinoma?
No, avelumab is used to treat Merkel cell carcinoma, not cause it. The available evidence indicates that avelumab is a therapeutic agent for metastatic MCC, and FDA warnings focus on immune-related adverse events and treatment failure, not causation of the disease.
What are the FDA warnings for avelumab?
The FDA has issued warnings regarding immune checkpoint inhibitors like avelumab concerning the risk of immune-related adverse events. For avelumab specifically, the prescribing information includes details on these risks and the potential for treatment failure, but does not indicate that avelumab causes Merkel cell carcinoma.
What is the timeline for harm from avelumab exposure?
For patients, harm typically involves immune-related adverse events during treatment or progression of MCC despite therapy. The timeline for progression can be weeks to months, as seen in clinical trials with regular response assessments.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.
Free Case & Eligibility Review
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.